Jia et al. demonstrated that high NORAD expression was related to poorer prognosis in ESCC patients treated with cisplatin-based therapy, revealing that NORAD overexpression could contribute to cisplatin resistance in ESCC cells. This evidence concerns the gene NORAD and esophageal squamous cell carcinoma.